Drug intelligence / Profile preview

PRD236256

Development stage: Unknown
Lead developer: UCB
Modality: Small Molecules
Administration: Oral

Overview

PRD236256 is an investigational small molecule developed by UCB for the treatment of epilepsy. It functions as a ligand for the synaptic vesicle protein 2A (SV2A), a protein integral to the regulation of neurotransmitter release in the central nervous system. SV2A has been successfully targeted by previous UCB anti-seizure medications, including levetiracetam and brivaracetam. PRD236256 is designed to provide potent and selective modulation of SV2A to reduce the neuronal hyperexcitability that characterizes epileptic seizures. The drug is currently being evaluated in Phase 2 clinical trials to assess its safety, pharmacokinetics, and efficacy in patients with epilepsy.

Targets

SV2A (Synaptic vesicle glycoprotein 2A)

Beyond the preview

Go deeper on PRD236256.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRD236256.

Explore the full profile